| Literature DB >> 24269459 |
A García-Ben1, F Gómez-Ulla2, M J Rodriguez-Cid3.
Abstract
CLINICAL CASE: We report a case of a 42 year-old male with a macular edema due to idiopathic juxtafoveal retinal telangiectasis type i, treated with 3 sequential injections of intravitreal bevacizumab (1.25 mg in 0.05 ml). Anatomical improvements were observed after one year of follow up. DISCUSSION: There is currently no general consensus regarding the treatment of unilateral idiopathic juxtafoveal telangiectasis. The therapeutic options are, grid laser photocoagulation, intravitreal triamcinolone, verteporfin photodynamic therapy, or anti-VEGF. Visual acuity and anatomical improvements were observed in this case after intravitreal bevacizumab. Thus, intravitreal bevacizumab seems to be effective to treat macular edema in idiopathic juxtafoveal telangiectasis type i.Entities:
Keywords: Anti-factor de crecimiento endotelial vascular; Anti-vascular endothelial growth factor; Bevacizumab; Edema macular; Idiopathic juxtafoveal telangiectasis; Macular edema; Optical coherence tomographic; Telangiectasias yuxtafoveales idiopáticas; Tomografía óptica de coherencia
Mesh：
Substances：
Year: 2013 PMID： 24269459 DOI： 10.1016/j.oftal.2013.01.006
Source DB: PubMed Journal: Arch Soc Esp Oftalmol ISSN： 0365-6691